racemetirosine has been researched along with Hyperpigmentation in 1 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stega, J | 1 |
| Noel, MS | 1 |
| Vandell, AG | 1 |
| Stega, D | 1 |
| Del Priore, G | 1 |
| Hoffman, S | 1 |
1 trial available for racemetirosine and Hyperpigmentation
| Article | Year |
|---|---|
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.
Topics: Aged; alpha-Methyltyrosine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; E | 2020 |